92950-39-5 Usage
Description
ACETYLTAXOL, 7-(P) is a biologically active paclitaxel derivative that exhibits interactions with tubulin assemblies in the brain. It is a white solid with unique chemical properties that make it a promising candidate for various applications in different industries.
Uses
Used in Pharmaceutical Industry:
ACETYLTAXOL, 7-(P) is used as a pharmaceutical agent for its potential role in treating brain-related disorders and diseases. Its interaction with tubulin assemblies in the brain makes it a promising candidate for developing new therapeutic approaches.
Used in Drug Delivery Systems:
ACETYLTAXOL, 7-(P) can be used in drug delivery systems to improve the targeting and efficacy of treatments for brain-related conditions. Its unique chemical properties and interactions with tubulin assemblies can be leveraged to develop novel drug delivery platforms, enhancing the bioavailability and therapeutic outcomes of the compound.
Used in Research and Development:
ACETYLTAXOL, 7-(P) can be utilized in research and development for studying the mechanisms of tubulin assembly interactions and their implications in brain function and disease. This knowledge can contribute to the advancement of our understanding of neurological processes and the development of new therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 92950-39-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,9,5 and 0 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 92950-39:
(7*9)+(6*2)+(5*9)+(4*5)+(3*0)+(2*3)+(1*9)=155
155 % 10 = 5
So 92950-39-5 is a valid CAS Registry Number.
InChI:InChI=1/C49H53NO15/c1-26-33(63-45(58)38(54)37(30-17-11-8-12-18-30)50-43(56)31-19-13-9-14-20-31)24-49(59)42(64-44(57)32-21-15-10-16-22-32)40-47(7,41(55)39(62-28(3)52)36(26)46(49,5)6)34(61-27(2)51)23-35-48(40,25-60-35)65-29(4)53/h8-22,33-35,37-40,42,54,59H,23-25H2,1-7H3,(H,50,56)/t33-,34-,35+,37-,38+,39+,40-,42-,47+,48-,49+/m0/s1
92950-39-5Relevant articles and documents
Method for preparing 7-acetyl paclitaxel
-
Paragraph 0024; 0028; 0032; 0034-0035; 0038-0040; 0043, (2018/03/28)
The invention discloses a method for preparing 7-acetyl paclitaxel. The method comprises the following steps: 1, acetylizing the seventh position and the tenth position of 10-Dab used as a raw material to prepare an intermediate 1; 2, carrying out a conde
Structure-activity relationship study of taxoids for their ability to activate murine macrophages as well as inhibit the growth of macrophage-like cells
Ojima, Iwao,Fumero-Oderda, Cecilia L.,Kuduk, Scott D.,Ma, Zhuping,Kirikae, Fumiko,Kirikae, Teruo
, p. 2867 - 2888 (2007/10/03)
A series of new taxoids modified at the C-3′, C-3′N, C-10, C-2 and C-7 positions has been designed, synthesized and evaluated for their potency to induce NO and TNF production by peritoneal murine macrophages (Mφ) from LPS-responsive C3H/HeN and LPS-hyporesponsive C3H/HeJ strains and human blood cells, and for their ability to inhibit the growth of Mφ-like cell lines J774.1 and J7.DEF3. The SAR-study has shown that the nature of the substituents at these positions have critical effect on the induction of TNF and NO production by Mφ. Positions C-3′ and C-10 are the most flexible and an intriguing effect of the length of the substituents at the C-10 position is observed for taxoids bearing a straight chain alkanoyl moiety. An aromatic group at the C-3′N and C-2 positions is required for the activity, while only hydroxyl or acetyl substituents seem to be tolerated at the C-7 position. The natural stereochemistry in the C-13 isoserine side chain of the taxoids is an absolute requirement for macrophage activation. It has also been clearly shown that there is no correlation between the ability of the taxoids to induce TNF/NO production in C3H/HeN Mφ and the cytotoxicity against Mφ-like cells.
Deacetylation of paclitaxel and other taxanes
Zheng, Qun Y.,Darbie, Lynn G.,Cheng, Xiaoqin,Murray, Christopher K.
, p. 2001 - 2004 (2007/10/02)
-